GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Channel Therapeutics
Channel Therapeutics, a neuroscience biotech, is valued in the private market based on the progress of its research programs. The potential post-IPO share price will depend on the results of preclinical and clinical trials of its drugs.
Share prices of companies in the market segment - Pharma neurology
Passage Bio (ticker symbol PSTG, not PTHS) is a biotech company specializing in developing gene therapies for the treatment of rare monogenic diseases of the central nervous system. We classify it as a Pharmaceutical (Neurology) company. The chart below shows the performance of this segment.
Broad Market Index - GURU.Markets
Channel Therapeutics is a pharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock price to assess the outlook for this industry.
Change in the price of a company, segment, and market as a whole per day
PTHS - Daily change in the company's share price Channel Therapeutics
Channel Therapeutics' daily share price fluctuations reflect the high volatility inherent in early-stage biotech companies. This metric is a measure of sensitivity to scientific data in neuroscience and serves as a key element in assessing risk.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Channel Therapeutics is a biotech company. This chart demonstrates the extreme volatility of the sector. Comparison with PTHS's dynamics, which depend on clinical trial results, helps assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Channel Therapeutics is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Channel Therapeutics
Channel Therapeutics' year-over-year performance is a story of drug development for neurological and psychiatric disorders. Its 12-month market cap depends entirely on progress in preclinical and early clinical trials, where the company must demonstrate the potential of its scientific platform to create effective and safe drugs.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Channel, as a private biotech, likely focuses on niche neurological diseases. Its growth depends on success in clinical trials. Its valuation will reflect investor confidence in its scientific platform, potentially outperforming the overall pharma sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Channel Therapeutics appears to be privately held or defunct. The ticker symbol PTHS is inactive. Analysis of its market performance is impossible. If such a company existed in the biotech sector, its value would be determined solely by clinical trial results, not economic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Channel Therapeutics
Channel Therapeutics operates in the neuroscience field, and its valuation is based on R&D expectations. Monthly fluctuations reflect progress in clinical trials. Positive data or partnership news can spark a surge in interest, while development delays put pressure on the stock.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
Channel Therapeutics is a private biotech company focused on developing drugs for the treatment of neurological diseases. Its future depends on success in research and clinical trials. The chart below shows the overall dynamics of the biotech sector, which is the backdrop for the development of such innovative startups.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Channel Therapeutics is a privately held biotech company whose shares are not publicly traded. There is no available data. Its potential performance, like that of other companies in the sector, will depend entirely on success in drug development, not on market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Channel Therapeutics
Channel Therapeutics, a neuroscience company, whose weekly stock price reflects progress in developing drugs for the nervous system. News about clinical trials, partnerships, and scientific breakthroughs drive the highly volatile short-term trends typical of the biotech sector.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
Channel Therapeutics is a private company, and information about it is limited. However, if its shares were traded, this chart would allow us to compare its hypothetical performance with the neuroscience sector, demonstrating how its potential could be linked to overall breakthroughs in the treatment of CNS diseases.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Channel Therapeutics is a privately held biotech company. If its shares were traded, their performance would likely be independent of the market. The chart would hypothetically show how news about clinical trials would trigger sharp movements, ignoring overall market fluctuations.
Market capitalization of the company, segment and market as a whole
PTHS - Market capitalization of the company Channel Therapeutics
Channel Therapeutics' market cap represents a financial bet on new approaches to treating neurological disorders. The company's stock price reflects investors' faith in its ability to develop drugs that target ion channels in the nervous system. Its performance is a barometer of hopes for a breakthrough in the treatment of conditions such as chronic pain and epilepsy.
PTHS - Share of the company's market capitalization Channel Therapeutics within the market segment - Pharma neurology
This company's market share in the neurosciences sector reflects its status as an early-stage research organization. Its market weight is determined not by revenue, but by the value of its intellectual property and the potential for scientific development in one of the most complex medical fields.
Market capitalization of the market segment - Pharma neurology
Channel Therapeutics is a biotech company focused on neuroscience. The chart below shows the overall market capitalization of this complex sector. Its dynamics are a barometer of investor hopes that science will unlock the keys to treating brain diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Channel Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of neurological diseases. Its market capitalization reflects the potential of its research. The chart below shows the economic weight of early-stage companies.
Book value capitalization of the company, segment and market as a whole
PTHS - Book value capitalization of the company Channel Therapeutics
Channel Therapeutics is an early-stage biopharmaceutical company. Its book value is primarily derived from cash raised from investors. The chart below shows how this capital is spent on research. It's a visualization of its financial "runway" for drug development.
PTHS - Share of the company's book capitalization Channel Therapeutics within the market segment - Pharma neurology
Channel Therapeutics is a biotech company focused on treating diseases of the nervous system. Its core capital is intellectual property. The share of physical assets will reflect its research-focused model, where its key assets are its high-tech laboratories.
Market segment balance sheet capitalization - Pharma neurology
Channel Therapeutics is a biotech company whose value is created in laboratories developing drugs for neurological diseases. It's a "light" model, based on science. The chart below shows how much the pharmaceutical industry relies on physical assets versus intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Channel Therapeutics' balance sheet represents capital invested entirely in developing drugs for the treatment of neurodegenerative diseases. The book value chart shows the financial resources focused on this complex task and serves as a measure of investor hopes for a scientific breakthrough.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Channel Therapeutics
Channel Therapeutics (likely a reference to Perception Neuroscience, part of Atai) develops drugs to treat neurological disorders. Like most early-stage biotechs, its value lies not in its assets but in its intellectual property. Its market capitalization reflects investors' faith in its scientific approach to complex brain diseases.
Market to book capitalization ratio in a market segment - Pharma neurology
Channel Therapeutics (presumably referring to one of its assets) is a biotech focused on neuroscience. Like any early-stage company, its value is determined by expectations. The chart clearly demonstrates how the market valuation, based on the potential of the scientific idea, far exceeds the modest value of the tangible assets.
Market to book capitalization ratio for the market as a whole
Channel Therapeutics is likely a privately held or recently acquired neuroscience company. The chart for such biotechs reflects a pure bet on science. Market valuation is not tied to assets but depends on progress in clinical trials. Success could lead to explosive growth, while failure could lead to a near-total loss of market capitalization.
Debts of the company, segment and market as a whole
PTHS - Company debts Channel Therapeutics
Channel Therapeutics operates at the forefront of neuroscience, developing new treatments. As with any biotech company without stable revenue, capital management is a key challenge. This chart shows how the company uses financial instruments to support its long-term, capital-intensive research programs.
Market segment debts - Pharma neurology
Channel Therapeutics is another biotech company focused on neuroscience. Like many R&D companies, its financial model is built on raising capital to fund preclinical and clinical trials. This chart provides industry context to help understand the typical financial needs of companies pursuing the long drug discovery journey.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Channel Therapeutics
Channel Therapeutics is a biotech company specializing in drugs for neurological diseases. Its activities are almost entirely focused on research and development. This chart shows how much of this expenditure the company covers with debt, a direct indicator of its financial risk in anticipation of breakthrough discoveries.
Market segment debt to market segment book capitalization - Pharma neurology
Developing drugs for neurological diseases, like Channel Therapeutics', requires massive R&D investments with uncertain outcomes. This chart illustrates the overall debt burden in the biotech sector. It allows one to assess how the company's financial model at an early stage compares to the average for this capital-intensive industry.
Debt to book value of all companies in the market
Channel Therapeutics is focused on neuroscience, another area with a long development cycle. Debt financing allows the company to conduct expensive clinical trials. The chart shows how their debt level compares to the overall market, which includes both mature and venture-backed companies.
P/E of the company, segment and market as a whole
P/E - Channel Therapeutics
This chart shows the valuation of Channel Therapeutics, a clinical-stage biopharmaceutical company focused on neuroscience. For a company without stable revenue, its value is determined by the potential of its developments. The chart serves as a barometer of investor sentiment regarding the likelihood of its drugs succeeding in clinical trials.
P/E of the market segment - Pharma neurology
This metric represents the average valuation for the biotech sector in which Channel Therapeutics operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark.
P/E of the market as a whole
Channel Therapeutics is a biotech company developing new treatments for neurological disorders. Like many early-stage companies, its value stems from the anticipation of future breakthroughs. This chart reflects the market's propensity for long-term investment in science. It allows one to assess how the overall investment climate impacts a company's ability to fund its research.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Channel Therapeutics
Channel Therapeutics is a biotech company, likely focused on developing drugs for neurological diseases, as its name suggests. Its future depends entirely on the success of scientific research, clinical trials, and regulatory approval. This graph will reflect investors' speculative expectations regarding a potential breakthrough in the treatment of nervous system diseases.
%20P%2FE%20Channel%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Channel-Therapeutics&v=1772602055581 "Chart of the company's future (projected) P/E Channel Therapeutics")
Future (projected) P/E of the market segment - Pharma neurology
Channel Therapeutics is a private biotech company focused on developing treatments for neurological diseases. Like many private biotechs, its success depends on clinical trial data. The chart shows public sector expectations, providing a benchmark for understanding the overall prospects in this field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772602055639 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Channel Therapeutics is a biotech company specializing in developing treatments for neurological diseases. Like many companies in this space, they rely on venture capital and investor sentiment. This chart, reflecting overall optimism, shows how willing the market is to fund long-term research, where the risk is high but the potential rewards are enormous.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772602055651 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Channel Therapeutics
Channel Therapeutics is a biopharmaceutical company developing new treatments for neurological disorders. This chart illustrates the financial picture of the early-stage biotech startup. There is currently no profit, as all resources are focused on preclinical research and development of drug candidates.
Profit of companies in the market segment - Pharma neurology
Estrella Immunopharma is a biotech company developing cell therapy for blood cancer. Like other companies in this field, its profitability is a question of future clinical success. This chart illustrates the state of a sector where massive investments in cutting-edge science are the norm, but financial results represent years of losses awaiting a breakthrough.
Overall market profit
Channel Therapeutics, formerly known as Pathos, is focused on developing therapies for cancer and neurological diseases. Like many early-stage biotech companies, its success or failure hinges on the results of clinical trials. This makes its story unaffected by the broader economic cycles visible in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Channel Therapeutics
Channel Therapeutics is likely an early-stage biotech focused on neuroscience. Profit projections for such companies are purely hypothetical and depend on future research and development success. The chart would reflect analysts' speculative bets on the company's scientific platform and its potential to treat nervous system disorders.
%20profit%20of%20the%20company%20Channel%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Channel-Therapeutics&v=1772602055984 "Graph of future (projected) profit of the company Channel Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma neurology
Channel Therapeutics is likely a privately held or recently established biotech company focused on neuroscience. Like any biotech startup, its future depends on successful clinical trials. This chart shows profitability forecasts for the pharmaceutical sector. It sets the general expectations against which new players must prove their scientific hypotheses.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772602056099 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
Channel Therapeutics is a biotech company specializing in drugs for the treatment of neurological disorders. The company's success depends on clinical results, not the current economic environment. However, this graph of overall revenue projections is important for assessing investor willingness to fund risky but potentially breakthrough projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772602056142 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Channel Therapeutics
Channel Therapeutics is a pharmaceutical company developing drugs for the treatment of neurological diseases. Like many biotech startups, it is in the early stages and has no stable revenue. The valuation shown in this chart is based solely on investors' faith in the company's scientific hypothesis and the potential success of its future clinical trials.
P/S market segment - Pharma neurology
Channel Therapeutics is a pharmaceutical company developing drugs for the treatment of neurological diseases. Currently in the research stage, its future revenue depends on the successful advancement of its candidates through clinical stages. This chart reflects the average valuation in the sector, allowing one to assess how the market views companies targeting complex CNS diseases.
P/S of the market as a whole
Channel Therapeutics is a biotech company focused on developing treatments for neurological diseases. Like many players in this field, its value is determined not by current revenue, but by the potential for future discoveries. This chart shows average market valuations and serves as a reminder of the speculative nature of early-stage biotech investing.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Channel Therapeutics
Channel Therapeutics is an early-stage biotech focused on treating neurological diseases. This chart shows how investors assess the future scientific and commercial potential of its developments. This assessment is based entirely on the success of preclinical and early clinical studies, which could lead to the development of breakthrough drugs.
%20P%2FS%20Channel%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Channel-Therapeutics&v=1772602056535 "The graph of the company's future (projected) P/S Channel Therapeutics")
Future (projected) P/S of the market segment - Pharma neurology
Channel Therapeutics is a biotech company focused on developing new treatments for neurological disorders. Its future depends on successful clinical trials and drug launches. This chart shows the market's estimate of the company's future sales compared to other players in its industry, demonstrating confidence in its scientific potential.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772602056582 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
Future revenue expectations in biotech are often tied to the development of drugs for diseases of the central nervous system. Channel Therapeutics, like many companies in this field, is working to develop new therapies for these complex conditions. Interest in such companies demonstrates the market's belief in the long-term potential of neuroscience.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772602056671 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Channel Therapeutics
Channel Therapeutics is an early-stage biotech focused on treating neurological diseases. Like many companies in this field, it does not yet generate commercial revenue. The revenue curve reflects the investment-funded research and development phases in anticipation of a future breakthrough.
Sales of companies in the market segment - Pharma neurology
Channel Therapeutics (formerly Pathos) is a biotech company focused on developing targeted therapies for the treatment of oncology. This chart shows the total revenue of pharmaceutical companies in the neuroscience segment. It demonstrates the market size and the need for innovative therapies for complex conditions, where Channel is building its business.
Overall market sales
Channel Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of neurological disorders. Being an early-stage company, its value lies in the potential of its scientific developments. This graph of the overall economic situation affects the availability of venture capital for funding long-term and capital-intensive biotech research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Channel Therapeutics
Channel Therapeutics is an early-stage biopharmaceutical company focused on developing treatments for neurological diseases. Its future depends entirely on success in R&D. The revenue guidance chart is highly speculative, reflecting only the longest-term expectations of analysts, dependent on positive clinical trial data.
%20sales%20of%20the%20company%20Channel%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Channel-Therapeutics&v=1772602057017 "Schedule of future (projected) sales of the company Channel Therapeutics")
Future (projected) sales of companies in the market segment - Pharma neurology
Channel Therapeutics (formerly Pathos) is a biotech company developing cancer treatments that overcome resistance to therapy. The company's success is entirely dependent on clinical trials. This chart illustrates projected sales for the entire neuroscience pharmaceutical segment, allowing one to assess overall expectations and growth potential in this field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772602057048 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Channel Therapeutics (formerly Phathom Pharmaceuticals) focuses on developing drugs for the treatment of acid-related gastrointestinal diseases. The company's commercial success depends on competition and physician acceptance. This general economic activity affects the healthcare market as a whole, determining the solvency of patients and insurers.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772602057097 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Channel Therapeutics
Channel Therapeutics is an early-stage biotech company focused on neuroscience. This metric reflects the financial realities of a life sciences startup. It demonstrates the required investment in preclinical and early clinical trials, which forms the foundation for creating future value and potential profits.
Market segment marginality - Pharma neurology
Channel Therapeutics operates at the forefront of neuroscience, developing new treatments for diseases of the central nervous system. For a clinical-stage company, its financial metrics reflect research expenditures. This chart allows you to evaluate its operational structure and capital efficiency compared to other neurobiology firms.
Market marginality as a whole
Channel Therapeutics (formerly Phathom Pharmaceuticals) focuses on developing new treatments for acid-related gastrointestinal diseases. Their business is driven by clinical trial success and competition with existing drugs. This overall profitability curve doesn't impact their research activities but is important for assessing the market potential of their future products.
Employees in the company, segment and market as a whole
Number of employees in the company Channel Therapeutics
Channel Therapeutics is an early-stage biopharmaceutical company focused on neuroscience. At this stage, a small but highly effective scientific team plays a key role. This graph shows the minimum team size typical for a company focused on basic research and preclinical development of new molecules.
Share of the company's employees Channel Therapeutics within the market segment - Pharma neurology
Channel Therapeutics, formerly known as Asieris, develops drugs in urologic oncology. This chart shows the percentage of urologists and oncologists in this niche that the company attracts. Its team is focused on finding new treatments for bladder cancer and other related diseases.
Number of employees in the market segment - Pharma neurology
Channel Therapeutics is a pharmaceutical company developing drugs for neurological disorders. This chart shows overall employment in the neuroscience research sector. For an early-stage company, it illustrates the broad talent landscape, which requires competition for the best scientists to advance its research.
Number of employees in the market as a whole
Channel Therapeutics is a biotech company specializing in developing drugs for the treatment of neurological diseases. The neuroscience sector requires long-term and expensive research, which means a stable workforce of scientists. This graph shows overall employment, with the biotech sector serving as an indicator of investment in long-term research projects and human capital.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Channel Therapeutics (PTHS)
Channel Therapeutics is a pharmaceutical company specializing in the treatment of neurological disorders. The high capitalization per employee, as seen in this chart, is typical of R&D-focused companies. The market evaluates not current sales, but the value of intellectual property and the potential of drugs being developed by a small but effective team.
%20of%20the%20company%20Channel%20Therapeutics%20(PTHS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Channel-Therapeutics-PTHS&v=1772602057410 "Chart of market capitalization per employee (in thousands of dollars) of the company Channel Therapeutics (PTHS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Channel Therapeutics is a biotech company focused on neuroscience research. Like other early-stage companies, their valuation is based on expectations. This metric allows investors to estimate the premium the market places on the potential of their research, relative to the small but highly skilled team of scientists working on breakthrough therapies.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772602057420 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Channel Therapeutics, as its name suggests, is a biotech company in the neuroscience field. In this field, a company's value is almost entirely determined by its intellectual property and progress in clinical trials. A high market capitalization per employee would reflect investor expectations for scientific potential, not current operations.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772602057443 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Channel Therapeutics (PTHS)
Channel Therapeutics is a private biotech company focused on developing drugs for neurological disorders. Like most R&D startups without approved products, their business is purely research. This chart reflects this reality, showing the net loss (investment in research) per employee.
%20Chart%20Channel%20Therapeutics%20(PTHS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Channel-Therapeutics-PTHS&v=1772602057454 "Company Profit Per Employee (in thousands of dollars) Chart Channel Therapeutics (PTHS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Channel Therapeutics is another biotech company focused on neuroscience. At the R&D stage, this metric doesn't reflect true value. The chart shows a benchmark for commercially successful companies. PTHS's goal is to successfully conduct clinical trials so that their intellectual property can generate revenues that exceed the industry average.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772602057498 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Channel Therapeutics (PTHS) appears to be an early-stage biotech startup focused on neuroscience. Such companies often remain under the radar until they generate significant data. This would be a significant negative for them, as the small team of founders and scientists is spending venture capital on research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772602057522 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Channel Therapeutics (PTHS)
At Channel Therapeutics, a company developing drugs for neurological diseases, this growth curve is at or near zero. Its future growth depends entirely on the success of clinical trials and the ability of a small team to bring a sought-after drug to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Channel-Therapeutics-PTHS&v=1772602057531 "Sales chart per company employee Channel Therapeutics (PTHS)")
Sales per employee in the market segment - Pharma neurology
Channel Therapeutics is a biotech company specializing in developing treatments for neurological diseases. It is an early-stage R&D company. This metric reflects the average revenue per employee in the segment. It helps investors understand how productive their research team is compared to other neuroscience biotechs, especially those already close to market.
Sales per employee for the market as a whole
Channel Therapeutics (PTHS) is an early-stage biopharmaceutical company focused on neuroscience. The company currently has no commercial revenue, and its activities are purely R&D. This chart for PTHS shows zero growth. Potential future growth would indicate successful licensing of their developments or a partnership with a major pharma company.
Short shares by company, segment and market as a whole
Shares shorted by company Channel Therapeutics (PTHS)
Channel Therapeutics (formerly Pathway) is a clinical-stage biotech focused on neuroscience. Like any biotech without revenue, its value is entirely dependent on future clinical data. This chart reflects the high skepticism of investors who are betting that its drug candidates will fail to reach their endpoints in trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Channel-Therapeutics-PTHS&v=1772602057613 "Short Shares Chart for the Company Channel Therapeutics (PTHS)")
Shares shorted by market segment - Pharma neurology
Channel Therapeutics (PTHS) is a pharmaceutical company focused on neuroscience, according to data. Such companies carry high research and development risks. This chart shows the total short position in the neuroscience pharmaceutical sector. It highlights the overall level of investor skepticism regarding the likelihood of clinical trial success in this complex field.
Shares shorted by the overall market
Channel Therapeutics (PTHS) is a clinical-stage biotech. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Channel Therapeutics (PTHS)
Channel Therapeutics (PTHS) is a clinical-stage biotech company working in neuroscience. This chart measures pure speculative hope. It shows when the stock is overbought on the slightest positive signal from the lab or oversold amid a long R&D cycle and capital burn.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Channel-Therapeutics-PTHS&v=1772602057723 "RSI 14 indicator chart for the company's stock Channel Therapeutics (PTHS)")
RSI 14 Market Segment - Pharma neurology
Channel Therapeutics (PTHS) is a biotech company focused on neurology. The "Pharma neurology" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether PTHS's growth is due to its R&D or whether the entire biotech sector is simply overheated by expectations.
RSI 14 for the overall market
Channel Therapeutics (PTHS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PTHS (Channel Therapeutics)
Channel Therapeutics is a biotech company focused on developing drugs for the treatment of neurological disorders. This chart shows the average target price. Analysts' forecasts are based on an assessment of preclinical and early clinical data, as well as the potential market size for their therapy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PTHS-Channel-Therapeutics&v=1772602057928 "A chart showing analyst consensus forecasts for the expected stock price. PTHS (Channel Therapeutics)")
The difference between the consensus estimate and the actual stock price PTHS (Channel Therapeutics)
Channel Therapeutics is a biotech company focused on developing drugs for neurological diseases. This chart measures the gap between the current share price and the consensus target price. It shows the potential analysts see in their early-stage R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PTHS-Channel-Therapeutics&v=1772602057970 "A chart showing the difference between the consensus forecast and the actual stock price. PTHS (Channel Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Channel Therapeutics is a company with little public information. Judging by the context "Pharma Neurology," it's a biotech startup in the neuroscience field. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe a breakthrough in brain disease treatment is possible.
Analysts' consensus forecast for the overall market share price
Channel Therapeutics (PTHS) is likely a micro-cap biopharmaceutical company focused on neuroscience. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Channel Therapeutics
Channel Therapeutics is likely a clinical-stage biotech focused on neuroscience. As their name suggests, they are developing drugs targeting ion channels—gateways in nerve cells. This chart is a pure indicator of their R&D confidence. It doesn't reflect revenue, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Pharma neurology
Channel Therapeutics (PTHS) is a biotech company specializing in developing drugs for neurological disorders. This chart shows the average index for the neurosector. It provides investors with a benchmark for how Channel Therapeutics, which operates in this complex field, compares to the sector average.
The AKIM Index for the overall market
Channel Therapeutics is an early-stage biotech company (likely private or microcap) developing ion channel modulators. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends and the availability of venture capital.
